缺血性卒中患者平均血小板体积水平与氯吡格雷抵抗的相关性分析

摘要/Abstract

摘要：

目的观察缺血性卒中患者的氯吡格雷抵抗（clopidogrel resistance，CR）与血小板平均体积（mean platelet volume，MPV）的关系。方法连续入组2013年3月～2014年1月期间在广州医科大学附属第三医院神经内科住院的缺血性卒中患者150例，所有患者均服用氯吡格雷75?mg/d，于用药前、用药物后10～14?d后应用比浊法测定血小板聚集率的变化，依据结果分为CR组和氯吡格雷敏感（clopidogel sensitivity，CS）组，对两组的一般资料、危险因素及MPV水平进行比较，同时采用多因素Logistic回归分析来确定MPV水平与CR的相关性。结果纳入的150例患者中，有44例（29.33%）发生CR，CS组106例。单因素分析中，CR组糖尿病、既往短暂性脑缺血发作（transient ischemic attack，TIA）病史及总胆固醇水平等均高于CS组（P值分别为＜0.001、＜0.001和0.004）；CR组MPV水平高于CS组［（9.55±0.40）fl vs（9.28±0.35）fl，P＜0.001］。而在多因素Logistic回归分析中显示，MPV水平［比值比（odds ratio，OR）10.555，95%可信区间（confidence interval，CI）2.524～44.134，P=0.001］、总胆固醇（OR?1.561，95%CI?1.051～2.318，P=0.027）、既往TIA（OR?6.537，95%CI?2.475～17.262，P=0.000）、糖尿病（OR?7.632，95%CI?2.620～22.228，P=0.000）与CR相关。结论 MPV水平是CR发生的独立危险因素之一，作为CR的预测与筛查工具有一定的价值。

文章导读： 本研究显示血小板平均体积与缺血性卒中患者氯吡格雷抵抗独立相关性，为临床诊断和预测氯吡格雷抵抗提供了新的思路。

关键词: 缺血性卒中; 血小板平均体积; 氯吡格雷抵抗; 预测价值

Abstract:

Objective To observe the relationship between the level of mean platelet volume and clopidogrel resistance in patients with ischemic stroke. Methods The study continuously chose 150 patients with ischemic stroke during March 2013 to January 2014 in Department of Neurology of the Third Affiliated Hospital of Guangzhou Medical University, all patients taking clopidogrel 75?mg/d, and then used turbidimetry to measure the platelet aggregation rate prior to the drug and 10~14 d after having taken clopidogrel. The patients were divided into clopidogrel resistance (CR) group and clopidogel sensitivity (CS) group according to the change of platelet aggregation rate, compared to the general information, risk factors, and the level of mean platelet volume (MPV). Multivariate Logistic regression analysis was used to identify the relationship with the level of MPV and CR. Results Total 150 patients with ischemic stroke were included, CR occurred in 44 of them (29.33%), CS group were 106 cases. In single factor analysis, the MPV level of CR group ([9.55± 0.40] fl vs [9.28±0.35]fl, P=0.000) were significantly higher than the CS group. The Logistic regression analysis showed that MPV levels (odds ratio [OR]10.555, 95% confidence interval [CI]2.524~44.134, P=0.001), total cholesterol (OR?1.561, 95%CI?1.051~2.318, P=0.027), the previous transient ischemic attack (TIA) (OR?6.537, 95%CI?2.475~17.262, P=0.000) and diabetes (OR?7.632, 95%CI?2.620~22.228, P=0.000) were correlated with CR. Conclusion The level of MPV is independent risk factors of CR, and it might be used to predict and screen CR in the early time.

Key words: Ischemic stroke; Mean platelet volume; Clopidogrel resistance; Predictive value

罗建华1，周伯荣1，钟广宏1，石红婷2，刘远波3，郑1. 缺血性卒中患者平均血小板体积水平与氯吡格雷抵抗的相关性分析[J]. 中国卒中杂志, 2015, 10(01): 50-55.

LUO Jian-Hua*, ZHOU Bo-Rong, ZHONG Guang-Hong, SHI Hong-Ting, LIU Yuan-Bo, ZHENG Xuan. . Relationship between the Level of Mean Platelet Volume and Clopidogrel Resistance in Patients with Ischemic Stroke[J]. Chinese Journal of Stroke, 2015, 10(01): 50-55.

参考文献

参考文献

1 Olson DM, Cox M, Pan W, et al. Death and rehospitalization after transient ischemic attack or acute ischemic stroke:one-year outcomes from the adherence evaluation of acute ischemic stroke-longitudinal registry[J]. J Stroke Cerebrovasc Dis, 2013, 22:e181-e188.

2 Tulner DM, Smith OR, De Jonge P, et al. Circulating cerebral S100B protein is associated with depressive symptoms following myocardial infarction[J]. Neuropsychobiology, 2009, 59:87-95.

3 Willoughby SR, Luu LJ, Cameron JD, et al. Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease[J]. Heart Lung Circ, 2014, 23:534-541.

4 Maruyama H, Fukuoka T, Deguchi I, et al. Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients[J]. Intern Med, 2014, 53:2575-2579.

5 石红婷, 周伯荣, 王融, 等. 比浊法血小板聚集试验的影响因素研究[J]. 国际检验医学杂志, 2012, 7:774-776.

6 Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk:a systematic review and meta-analysis[J]. J Thromb Haemost, 2010, 8:148-156.

7 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南[J]. 中华神经科杂志, 2010, 4:146-153.

8 Han SW, Kim SH, Lee JY, et al. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism[J]. Eur Neuro1, 2007, 57:96-102.

9 中国营养学会. 中国居民膳食指南(2011年修订版)[M]. 拉萨:西藏人民出版社, 2011:97-102.

10 World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic[M]. Geneva:WHO, 1998.

11 中国高血压防治指南修订委员会. 中国高血压防治指南[J]. 中华心血管病杂志, 2011, 39(7):579-616.

12 Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates:ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update):A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2009, 120:2271-2306.

13 Intemational Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes[J]. Diabetes Care, 2009, 32:1327-1334.

14 Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369:11-19.

15 Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation, 2003, 107:2908-2913.

16 Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its harmacologically active metabolite[J]. Drug Metab Dispos, 2010, 38:92-99.

17 Simon T, Vemmyft C, Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360:363-375.

18 Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45:2160-2236.

19 Taglieri N, Bacchi Reggiani ML, Palmerini T, et al. Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine diphosphate after percutaneous coronary intervention[J]. Am J Cardiol, 2014, 113:1807-1814.

20 Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent[J]. Thromb Res, 2009, 124:46-51.

21 Zhou BR, Shi HT, Wang R, et al. Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction[J]. J Neurol, 2013, 260:2928-2937.

22 Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA, 2010, 30:754-762.

23 Lance MD, Sloep M, Henskens YM, et al. Mean platelet volume as a diagnostic marker for cardiovascular disease:drawbacks of preanalytical conditions and measuring techniques[J]. Clin Appl Thromb Hemost, 2012, 18:561-568.

24 Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patientswith stable coronary artery disease[J]. Am Coll Cardiol, 2008, 52:743-749.

25 Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study[J]. Thromb Res, 2010, 12:406-412.

26 Vizioli L, Muscari S, Muscafi A, et al. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases[J]. Int J Clin Pract, 2009, 6:1509-1515.

27 Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment[J]. Platelets, 2008, 19:111-114.

28 Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus[J]. Platelets, 2004, 15:475-478.

[1]	吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371.
[2]	伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170.
[3]	王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177.
[4]	崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188.
[5]	刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208.
[6]	徐莹鑫, 张爽, 周晓梅, 袁景林, 赵留庄, 杨海华. 非狭窄性颈动脉斑块与前循环不明原因栓塞性卒中的相关性研究 [J]. 中国卒中杂志, 2022, 17(11): 1233-1237.
[7]	程实, 李静, 郭军平, 胡爱香, 于鑫玮, 韩玮, 梁瑛, 张越巍, 冀瑞俊. 急性卒中患者住院期间感染的临床特征及危险因素分析[J]. 中国卒中杂志, 2022, 17(10): 1065-1070.
[8]	向薇, 徐璐瑶, 张曼曼, 魏红春, 梁志刚. 缺血性卒中急性期磁敏感加权成像不对称突出静脉征的发生率及影响因素分析[J]. 中国卒中杂志, 2022, 17(10): 1097-1102.
[9]	赵永瑞, 刘展会. 弥散张量成像在缺血性卒中患者运动功能预后评估中的研究进展[J]. 中国卒中杂志, 2022, 17(10): 1114-1119.
[10]	张伯煜, 郭玉成, 崔玉霞, 李英丽, 吕雨梅. 急性缺血性卒中患者就医行为决策现状及影响因素研究进展[J]. 中国卒中杂志, 2022, 17(10): 1127-1132.
[11]	吴亭亭, 刘亚飞, 闫世曦, 武一平, 张忠波, 张邯菲, 房娉平. “互联网+”在急性缺血性卒中救治中的应用进展[J]. 中国卒中杂志, 2022, 17(10): 1133-1138.
[12]	徐蔚海, 李顺, 程安琪. 青年卒中的诊治：勿过激[J]. 中国卒中杂志, 2022, 17(09): 915-918.
[13]	张一歌, 张婉, 张璐阳, 王鑫, 丁澜, 王玉莹, 裴璐璐, 方慧, 许予明, 宋波. 责任动脉闭塞与夹层相关缺血性卒中复发的相关性分析[J]. 中国卒中杂志, 2022, 17(09): 932-936.
[14]	吕微, 王安心, 田雪, 张晓丽, 许玉园, 孟霞. 心血宁胶囊对伴高同型半胱氨酸水平缺血性卒中患者短期功能预后的影响[J]. 中国卒中杂志, 2022, 17(09): 972-976.
[15]	张心邈, 潘岳松, 向祥龙, 王拥军, 孟霞. 早期临床路径干预改善卒中医疗服务质量关键绩效指标研究[J]. 中国卒中杂志, 2022, 17(09): 977-984.